<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50348">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01997229</url>
  </required_header>
  <id_info>
    <org_study_id>ECU-MG-301</org_study_id>
    <secondary_id>2013-003589-15</secondary_id>
    <nct_id>NCT01997229</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Turkey: Turkish Pharmaceuticals and Medical Devices Institution</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if eculizumab is safe and effective for the
      treatment of refractory generalized Myasthenia Gravis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change in total MG-ADL score</measure>
    <time_frame>End of study (Week 26/ Visit 17)</time_frame>
    <safety_issue>No</safety_issue>
    <description>change from baseline in MG-ADL total score @Week 26 for eculizumab as compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall safety and tolerability of eculizumab</measure>
    <time_frame>end of study (week 26)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events, vital signs, laboratory assessments, Physical Exams, and ECGs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Refractory Generalized Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological/Vaccine:  Eculizumab Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks 5-26</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo contains the same buffer components without the active ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks 5-26</description>
    <arm_group_label>Eculizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female patients ≥18 years old

          -  Diagnosis of MG made by the following tests:

               1. Positive serologic test for anti-AChR Abs as confirmed at screening, and

               2. One of the following:

                    1. History of abnormal neuromuscular transmission test demonstrated by
                       single-fiber electromyography (SFEMG) or repetitive nerve stimulation, or

                    2. History of positive anticholinesterase test, e.g. edrophonium chloride
                       test, or

                    3. Subject has demonstrated improvement in MG signs on oral cholinesterase
                       inhibitors, as assessed by the treating physician.

          -  MGFA Clinical Classification Class II to IV at screening.

          -  MG-ADL total score must be ≥6 at screening

          -  Subjects who have:

               1. Failed treatment with at least two immunosuppressive agents. Or,

               2. Failed treatment with at least one immunosuppressive agent and require chronic
                  plasma exchange or IVIg

        Key Exclusion Criteria:

          -  History of thymoma or other neoplasms of the thymus

          -  History of thymectomy within 12 months prior to screening

          -  MGFA Class I or MG crisis at screening (MGFA Class V)

          -  Use of rituximab within 6 months prior to screening

          -  Use of IVIg or PE within 4 weeks prior to screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals</last_name>
    <email>clinicaltrials@alxn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco-Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc.</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California-Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc.</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa College of Medicine</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc.</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Inc.</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc.</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Buffalo General Hospital</name>
      <address>
        <city>Lockport</city>
        <state>New York</state>
        <zip>14094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc.</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital For Special Surgery/New York Presbyterian Hospital Cornell Campus</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc.</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wesley Neurology Clinic</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc.</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc.</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc.</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanamaki General Hospitals</name>
      <address>
        <city>Hanamaki-shi</city>
        <state>Iwate-Ken</state>
        <zip>025-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc.</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHO Nagasaki Kawatana Medical Center</name>
      <address>
        <city>Higashisonogi-gun</city>
        <state>Nagasaki-Ken</state>
        <zip>859-3615</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals, Inc.</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, Mellion ML, Benatar MG, Farrugia ME, Wang JJ, Malhotra SS, Kissel JT; MG Study Group. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013 Jul;48(1):76-84. doi: 10.1002/mus.23839. Epub 2013 Apr 30.</citation>
    <PMID>23512355</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>November 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myasthenia Gravis</keyword>
  <keyword>Eculizumab</keyword>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
